Amryt seeks to have rare condition drug approved for payment
The Dublin company is in discussion with regulators in Britain and France to have metreleptin, a treatment for abnormal distribution of fat in the body, approved for payment reimbursement
Amryt, the Dublin-based rare drug developer, is in talks with medicines regulators in Britain and other European countries to get its treatments approved for payment reimbursement.
Britain is one of the remaining large European markets where metreleptin, a treatment for lipodystrophy, is yet to be approved for payment following its launch last year. The medical condition involves an abnormal distribution of fat in the body.
Joe Wiley, Amryt's chief executive, said last week that it...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
‘I always had entrepreneurial ambitions and this was first-hand evidence of an unmet need’
Neuromod’s chief executive Dr Ross O’Neill says his company’s Lenire device, which aids tinnitus sufferers, can establish a sizeable market — particularly in the US among military veterans
PM Group reports 30% profits increase and announces 200 new jobs in Ireland
The project delivery firm said that pharmaceutical projects accounted for almost two-thirds of its overall revenue for 2020, which rose to almost €400 million
Neuromod Devices to double Irish headcount within next year
The medtech company, which specialises in neuromodulation devices indicated for the treatment of tinnitus, said it hopes to roll out its product in European countries such as France, Spain and the Netherlands